Avanafil
Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
Grundinformationen
- CAS
330784-47-9- Standard-SMILES
COc1ccc(CNc2nc(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl- InChIKey
WEAJZXNPAWBCOA-INIZCTEOSA-N- Summenformel
- C23H26ClN7O3
- Durchschnittliche Molmasse
- 483,96 g/mol
- Monoisotopische Masse
- 483,17856537
Namen und Bezeichner
- Bevorzugter Name
- Avanafil
- IUPAC
- 4-{[(3-Chloro-4-methoxyphenyl)methyl]amino}-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-[(pyrimidin-2-yl)methyl]pyrimidine-5-carboxamide
- Englischer Name
- Avanafil
- Summenformel
- C23H26ClN7O3
- Molmasse
- 483.95
Namen und Synonyme
Stendravanafilavanfil4-((3-chloro-4-Methoxybenzyl)aMino)-2-(2-(hydroxyMethyl)pyrrolidin-1-yl)-N-(pyriMidin-2-ylMethyl)pyriMidine-5-carboxaMide(S)-4-((3-Chloro-4-Methoxybenzyl)aMino)-2-(2-(hydroxyMethyl)pyrrolidin-1-yl)-N-(pyriMidin-2-ylMethyl)pyriMidine-5-carboxaMideU 53U-53D03217AVANAFEAvanafi
Datenbank-Bezeichner
- CAS
330784-47-9- PubChem CID
- 9869929
- DTXSID
DTXSID50186727- ChEMBL
CHEMBL1963681- ChEBI
CHEBI:66876- UNII
- DR5S136IVO
- EC Number
- 841-424-3
- Nikkaji
- J2.782.076J
Eigenschaften
Physikochemische Eigenschaften
- Schmelzpunkt
- 150 · 150-152°C
- Dichte
- 1.372 · 1.372
- storage temp.
- -20 °C · Sealed in dry,Store in freezer, under -20°C
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly, Heated)
- Aggregatzustand
- Solid
- pka
- 11.84 · 11.84±0.46(Predicted)
- Farbe
- White to Off-White
- InChIKey
- WEAJZXNPAWBCOA-INIZCTEOSA-N
- SMILES
- C1(N2CCC[C@H]2CO)=NC=C(C(NCC2=NC=CC=N2)=O)C(NCC2=CC=C(OC)C(Cl)=C2)=N1
- CAS Datenbank
- 330784 · 330784-47-9(CAS DataBase Reference)
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sicherheitsdaten
- wgk
- WGK 3
- hs_code
- 29339900
- Speicherklasse
- 11 - Combustible Solids
Chemie und Industrie
Anwendungen
BeschreibungAvanafil (Zepeed) was approved by the Korean Health Ministry for the treatment of erectile dysfunction (ED) in August 2011. Avanafil is a highly selective type 5 phosphodiesterase (PDE5) inhibitor. Avanafil is reported to be the most selective PDE5 inhibitor on the market. The onset of Tmax and half-life also varies among the marketed PDE5 inhibitors. Sildenafil has a Tmax at 1 h and a half-life of 3–5 h. Vardenafil is somewhat similar with a Tmax of 0.6 h and a half-life of 4–6 h. Tadalafil has the longest half-life among the marketed drugs with a half-life of 17 h. Avanafil has a fast onset of action reaching Tmax in 0.6 h with a half-life of 1.2 h. A synthesis of avanafil (TA-1790) is described in the patent literature. The main elimination route of avanafil is through the bile and feces. Avanafil was also found to be reabsorbed through enterohepatic recirculation.
VerwendenAvanafil is a highly selective PDE5 inhibitor with IC50 of 1 nM.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Zugehörige Reaktionen
2
Notizen zur Verbindung
Wird geladen…